BioSpace News Archive

Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended March 31, 2023 and provided an update on the Company’s operations.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced it will report its first quarter 2023 financial results and provide a corporate update following market close on Thursday, May 11, 2023.

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is pleased to announce the availability across Canada of its new prescription treatment RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray).

Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson), the largest health system serving the greater Philadelphia area and Southern New Jersey.

ARTHEx Biotech S.L. announced the closing of its €42 million Series B financing round led by Columbus Venture Partners, with participation from new investors, the European Innovation Council (EIC), Hadean Ventures, and Sound Bioventures.

Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three months ended March 31, 2023.

KaliVir Immunotherapeutics, Inc. today announced that its Director of Immunology, Ravikumar Muthuswamy , Ph.D., will present " Novel Oncolytic therapy VET3-TGI restricts TGFβ1 and augments Type-1 immune response in TME, in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation and ventricular tachycardia, announced the completion of enrollment in its Cryocure-VT trial of ultra-low temperature cryoablation for the treatment of monomorphic ventricular tachycardias.

Sensorion announces that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 24, 2023, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France.